Referenser Gynekologi

1. Regional Riktlinje för antikonception, Region Skåne
2. Gemzell-Danielsson K, Schellschmidt I, Apter D, ”A randomized, phase II study describing the efficacy, bleeding profile, and safety of two lowdose levonorgestrel-releasing intrauterine contraceptive systems and Mirena”, Fertility & Sterility, 2012 Mar;97(3):616-22.
3. Medical eligibility criteria for contraceptive use, WHO 2015
4. Regine Sitruk-Ware,” Hormonal contraception and thrombosis”, Fertility & Sterility, 2016 Nov;106(6):1289-1294
5. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E,” Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestogen doses: Danish cohort study”, 2011-9 BMJ. 2011 Oct 25;343:d6423
6. Lina S Mørch, Charlotte W Skovlund, Philip C Hannaford, Lisa Iversen, Shona Fielding, Øjvind Lidegaard, “Contemporary Hormonal Contraception and the Risk of Breast Cancer”, The New England Journal of Medicine, 2017 Dec 7;377(23):2228-2239
7. Junge, W., Mellinger, U., Parke, S. et al., ”Metabolic and Haemostatic Effects of Estradiol Valerate/Dienogest, a Novel Oral Contraceptive”, Clin. Drug Investig, 31, 573–584 (2011)
8. Sharon J Phillips, Naomi K Tepper, Nathalie Kapp, Kavita Nanda, Marleen Temmerman, Kathryn M Curtis, ” Progestogen-only contraceptive use among breastfeeding women: a systematic review”, Contraception, 2016 Sep;94(3):226-52
9. Naomi K Tepper, Sharon J Phillips, Nathalie Kapp, Mary E Gaffield, Kathryn M Curtis, “ Combined hormonal contraceptive use among breastfeeding women: an updated systematic review”, Contraception, 2016 Sep;94(3):262-74
10. Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E, ”Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and metaanalysis”, Lancet 2010 Feb 13;375(9714):555-62. Epub 2010 Jan 29.
11. SFOG-råd för menopausal hormonbehandling 2019 (pdf), reviderad 2021, SFOG
12. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI,”ESHRE Guideline: management of women with premature ovarian insufficiency”, Hum Reprod, 2016;31(5):926-37
13. Scarabin P-Y,“ Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis”, Climacteric 2018; 21:341-345.
14. Anagnostis P, Paschou SA, Katsiki N, Krikidis D, Lambrinoudaki I et al,” Menopausal hormone therapy and cardiovascular risk. Where are we now?”, Curr Vasc Pharmacol. 2018; 8
15. Abdi F, Mobedi H, Bayat F, Mosaffa N, Dolatian M, et al,” The Effects of Transdermal Estrogen Delivery on Bone Mineral Density in Postmenopausal Women: A Meta-analysis”, Iran J Pharm Res. 2017;16(1):380-389.
16. Collaborative Group on Hormonal Factors in Breast Cancer,” Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer”, Lancet 1997;350:1047-1059
17. Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, Hoti F, Vattulainen P, et al. ”Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study”, Menopause. 2016;23(11):1199-1203.
18. Dueñas-Garcia OF, Sullivan G, Hall CD, Flynn MK, O'Dell K,”Pharmacological Agents to Decrease New Episodes of Recurrent Lower Urinary Tract Infections in Postmenopausal Women. A Systematic Review”, Female Pelvic Med Reconstr Surg. 2016;22(2):63-9
19. Behandling av östrogenbristsymtom, Nationellt Vårdprogram Bröstcancer (kunskapsbanken.cancercentrum.se)
20. Leminen H, Hurskainen R, ”Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety”, International Journal of Women´s Health 2012; 4: 413-421
21. Matteson K A et al,” Non-surgical management of heavy menstrual bleeding: A systematic review and practice guidelines”, Obstet Gynecol.
22. 2013; 121(3): 632-643
23. Nationella Riktlinjer för vård vid endometrios, Socialstyrelsen (socialstyrelsen.se)
24. Vårdprogram för Endometrios, Region Skåne, Vårdprogram - Region Skåne (skane.se)
25. Jack D Sobel, “Recurrent vulvovaginal candidiasis”, Am J Obstet Gynecol, 2016, Jan;214(1):15-21 25) Lopez LM, Kaptein AA, Helmerhorst FM,” Oral contraceptives containing drospirenone for premenstrual syndrome”, Cochrane Review 2009
26. Vaccination mot HPV, Folkhälsomyndigheten (folkhalsomyndigheten.se)
27. Riktlinjer för hypertonisjukdomar under graviditet 2019. Reviderad 2021, SFOG (sfog.se)
28. Kaplan YC, Richardson JL, Keskin-Arslan E, Erol-Coskun H, Kennedy D, "Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis", Reprod Toxicology 2019 Jun;86:1-13
29. Klormadinonacetat och nomegestrolacetat: Åtgärder för att minimera risken för meningiom, Läkemedelverket, 2022; x_Zoely-DHPC Svensk_14-11-2022 (lakemedelsverket.se)
30. Läkemedel vid klimakteriesymtom, menopausal hormonbehandling (MHT), Läkemedelsverket, 2022; Läkemedel vid klimakteriesymtom, menopausal hormonbehandling (MHT) – behandlings‌‌­rekommendation,  Läkemedelsverket (lakemedelsverket.se)
31. MHT, The British Menopaus Society, 2018 ; HRT-Practical-Prescribing-AUG2018.pdf (pdf)
32. MHT, Australasian Menopaus Society, 2023; AMS Guide to MHT/HRT Doses Australia only - Australasian Menopause Society (menopause.org.au)